384 results on '"Ghielmini, Michele"'
Search Results
2. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials
3. Follicular Lymphoma
4. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
5. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
6. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
7. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
8. Choosing wisely in oncology: necessity and obstacles
9. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
10. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
11. Risk factors for renal toxicity after inpatient cisplatin administration
12. Primary Cutaneous Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma
13. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
14. How I treat mantle cell lymphoma
15. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
16. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
17. Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
18. Prognostic impact of monocyte count at presentation in mantle cell lymphoma
19. Managing newly diagnosed follicular lymphoma: state of the art and future perspectives
20. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
21. Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide
22. Patient benefits of maintenance immunotherapy
23. Incidence, risk factors and outcome of histological transformation in follicular lymphoma
24. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
25. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials
26. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
27. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
28. Diagnostic Performance of 18F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis
29. Controversies in the Treatment of Follicular Lymphoma
30. A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group
31. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites
32. Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials
33. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
34. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)
35. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
36. Overview of Antibody Therapy in B-Cell Non-Hodgkinʼs Lymphoma
37. Prognostic impact of immunoglobulin genes somatic hypermutation and chromosome 11q22-23 deletion in classical mantle cell lymphoma: A study from the Swiss Group for Clinical Cancer Research (SAKK)
38. Mantle Cell Lymphoma: New Treatments Targeted to the Biology
39. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkinʼs lymphoma
40. Weekly x 4 Induction Therapy with the Anti-CD20 Antibody Rituximab: Effect on Circulating t(14;18)+ Follicular Lymphoma Cells
41. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma
42. Feasibility and myeloprotective effect of high-dose amifostine combined with high-dose cyclophosphamide.
43. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
44. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03
45. External Validation and Revision of Thrombosis Lymphoma /Throly/ Score
46. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
47. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
48. The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer
49. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
50. ALK-positive large B-cell lymphoma - report of the first primary cutaneous case
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.